Performance Evaluation of Mpox Molecular POC Diagnostics

ConditionMonkey Pox
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorFoundation for Innovative New Diagnostics, Switzerland

About this trial

PP016 is a FIND-sponsored retrospective clinical performance study evaluating rapid molecular point-of-care (mPOC) tests for the detection of Mpox virus (MPXV) using archived lesion swab specimens collected in Uganda. Conducted at the Central Public Health Laboratory (CPHL) in Kampala, the study compares up to three investigational assays-Genes2Me VZV-Q, KH Medical RADI-ONE Mpox, and SD Biosensor STANDARD M10 MPX/OPX-against the BioPerfectus laboratory PCR reference test. The primary objective is to determine the sensitivity and specificity of each assay for detecting MPXV in archived positive and negative samples, while secondary analyses assess performance by Ct value and viral clade. The study uses a blinded, non-interventional case-control design with de-identified specimens collected since 2020. Approximately 80 samples per device evaluation are included. PP016 was initiated in response to ongoing mpox outbreaks and the need for accurate decentralized diagnostics in low-resource settings. The study complies with ISO 20916, ICH-GCP principles where applicable, and Ugandan ethical and regulatory requirements, with findings expected to support future regulatory approvals and implementation of rapid mpox diagnostics in low- and middle-income countries

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Lesion swabs stored in VTM/UTM (non-inactivating)

Aliquot with sufficient volume to run the reference PCR and at least one index test (≥2600 μL per pair reference-index tests: ideally at least 1400 μL for 3 index tests and 1200 μL for reference PCR, including 1 possible repeat per test)

Available PCR result for specimen selection (i.e. confirmed MPXV positive or negative)

Samples collected from 2020 onwards.

Disqualifiers

Unknown date of collection

>3 freeze-thaw cycles of sample.

Samples collected with expired swab collection devices or UTM/VTM

Trial population

The study population consists of archived skin lesion swabs specimens. These were previously collected from individuals suspected of mpox infection - confirmed by PCR as MPXV positive or negative - under research studies and/or public health surveillance protocols during past and ongoing mpox outbreaks and available in the selected clinical sites.

Trial design

Design model

Case-control

Time perspective

Retrospective

Treatments tested in this trial

  • MPOX IVD test

    Diagnostic test

    Each (negative and positive) sample will be tested on the standard of reference and the investigational IVD

Treatment groups

80 Participants
are divided into 2 treatment groups
Group A: Positive samples1 intervention
Group B: Negative samples1 intervention

Trial outcomes

Primary outcomes

1

Point estimates of sensitivity, specificity, positive and negative predictive value (PPV and NPV respectively) with 95% confidence intervals.

Point estimates of sensitivity, specificity, positive and negative predictive value (PPV and NPV respectively) with 95% confidence intervals.

Time frame
July-August 2026

Secondary outcomes

1

Point estimates of sensitivity/PPA stratified by Ct values of the reference PCR test.

Point estimates of sensitivity/PPA stratified by Ct values of the reference PCR test.

Time frame
July-August 2026
2

Point estimates of sensitivity/PPA and specificity/NPA with 95% confidence intervals stratified by virus clade.

Point estimates of sensitivity/PPA and specificity/NPA with 95% confidence intervals stratified by virus clade.

Time frame
July-August 2026

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: